Baylor Endocrine Center

Dallas, Texas 75246-1906

0 studies enrolling now · 17 studies all time

What they study most

Comparative Effectiveness of Glycemia-lowering Medications, Diabetes Mellitus, Type 2, Diabetes Type 2, Diabetes, Type 1, Diabetes, Type I, Hepatitis C Virus Infection, Hepatitis C, Chronic, Obesity, Obesity and Diabetes Mellitus, Type 2, Overweight, Type 1 Diabetes, Type 1 Diabetes Mellitus

Studies at this site

• A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes — Completed
• Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients — Completed
• A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection — Stopped early
• A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus — Completed
• CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes — Completed
• Gilead Sustained Virologic Response (SVR) Registry — Completed
• A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®) — Completed
• A 2-Month Safety Follow-Up Trial — Completed
• A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects — Completed
• A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes — Completed
• Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler — Stopped early
• Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes — Completed
• Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks — Stopped early
• Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes — Completed
• Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up — Completed
• Weight Loss Study for People With Type 2 Diabetes — Completed
• Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity — Completed